Enhanced CAR-T Cell Therapy through Synergistic Combinations
Legal Citation
Summary of the Inventive Concept
A novel system integrating genetically engineered T cells with disrupted Regnase-1 and/or TGFBRII genes with distinct technologies like AI, IoT, blockchain, and new materials, enhancing CAR-T cell therapy through improved monitoring, control, and personalized treatment.
Background and Problem Solved
Chimeric antigen receptor (CAR) T-cell therapy, despite its promise, faces limitations in terms of T cell growth, persistence, and personalized treatment. The original patent addresses some of these limitations by genetically engineering T cells with disrupted Regnase-1 and/or TGFBRII genes. However, further improvements can be achieved by integrating these engineered T cells with other technologies to create a more powerful and efficient system.
Detailed Description of the Inventive Concept
The new inventive concept combines the genetically engineered T cells with disrupted Regnase-1 and/or TGFBRII genes from the original patent with four distinct technologies: AI-powered analytics for real-time monitoring of T cell growth and persistence, blockchain technology for secure storage and management of patient-specific treatment data, nanomaterials for enhanced T cell expansion and viability, and IoT-enabled bioreactors for real-time monitoring and control of T cell culture conditions. This synergistic combination enables improved CAR-T cell therapy through enhanced monitoring, control, and personalized treatment.
Novelty and Inventive Step
The new claims introduce a novel combination of genetically engineered T cells with disrupted Regnase-1 and/or TGFBRII genes and distinct technologies, which is not obvious from the original patent. The inventive step lies in the integration of these components to create a more powerful and efficient system for CAR-T cell therapy.
Alternative Embodiments and Variations
Alternative embodiments may include integrating the genetically engineered T cells with other AI-powered tools, such as machine learning algorithms for predicting and optimizing T cell-mediated anti-tumor responses. Variations may also involve using different nanomaterials or IoT-enabled bioreactors to enhance T cell expansion and viability.
Potential Commercial Applications and Market
The enhanced CAR-T cell therapy system has significant commercial potential in the cancer treatment market, particularly in personalized medicine and targeted therapies. The system's ability to improve monitoring, control, and personalized treatment can lead to better patient outcomes and increased adoption in clinical settings.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy, genetic engineering of T cells, and biotechnology with a focus on CAR-T cell development and genetic modification techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher or biotechnologist with advanced degrees in molecular biology, immunology, or bioengineering, experienced in CRISPR gene editing, cell therapy techniques, and advanced biotechnological methodologies
Obviousness Rationale
A person of ordinary skill would recognize that integrating advanced monitoring and manufacturing technologies with genetically engineered T cells represents a predictable extension of the source patent's core innovation. The combination of genetic modification techniques with digital technologies like AI, blockchain, and IoT follows established trends in personalized medicine and biotechnology. The PTD's variations represent logical combinations of known techniques that would be apparent to a skilled practitioner seeking to improve CAR-T cell therapy outcomes.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,574 |
|---|---|
| Title | Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence |
| Assignee(s) | CRISPR THERAPEUTICS AG |